acetylcholinesterase inhibitors

acetylcholinesterase inhibitors

Drugs that block the action of the enzyme ACETYLCHOLINESTERASE which quickly breaks down the neurotransmitter acetylcholine. This neurotransmitter is the linking agent between nerve cells in the outer layer (cortex) of the brain. The early impairment of cognitive function found in a common forms of dementia known as dementia with Lewy bodies (DLB) is associated with a reduction in acetylcholine levels. These drugs, by inhibiting, acetylcholine breakdown, have been found helpful in reducing the severity of the early stages of dementia. They cannot be expected to cure or even delay progress of the dementia. The drug group includes DONEPEZIL, GALANTAMINE and RIVASTIGMINE.
References in periodicals archive ?
Presently, several referenced natural acetylcholinesterase inhibitors are known, including physostigmine, galantamine, and huperzine A.
Denepezil (Aricept): It belongs to the group of acetylcholinesterase inhibitors.
Given that the currently approved therapies for AD are limited to acetylcholinesterase inhibitors and glutamate receptor antagonists, the pipeline offers a broad range of treatment options that may possess disease-modifying properties.
The effectiveness and safety of the coadministration of memantine HCl extended release and acetylcholinesterase inhibitors (AChEIs), together with donepezil HCl, was based on the results of a randomized and double-blind, placebo-controlled study of 677 outpatients on a stable dose of AChEIs.
According to Roivant, SB742457 improves cognition in preclinical models, and preliminary preclinical data suggest a potential additive or synergistic effect when 5-HT6 antagonists are added to acetylcholinesterase inhibitors, one of the two classes of drugs approved by the FDA for the treatment of Alzheimer's disease.
A number of approaches were developed to enhance cholinergic function, the most successful of which has been the use of acetylcholinesterase inhibitors that work by inhibiting the degradation of the Ach (Ballard, 2002).
The first set is known as acetylcholinesterase inhibitors, which are approved for use in patients with mild or moderate forms of dementia.
The only drugs approved currently are acetylcholinesterase inhibitors but they do not correct the basic pathology of the disease, beta amyloid deposits and neurofibrillary tangles.
The efficacy and safety of NAMENDA XR was established in a 24 week, randomized, double-blind, placebo-controlled trial of 677 outpatients on a stable dose of acetylcholinesterase inhibitors (AChEl), concluded the company.
These patients were also taking anti-dementia drugs known as acetylcholinesterase inhibitors said the findings published in the Journal of the American Medical Association.
Researchers have postulated that nicotinic receptor agonists could have similar benefits to acetylcholinesterase inhibitors, but with a better side-effect profile.

Full browser ?